Compare CABO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | REPL |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 407.1M |
| IPO Year | 2015 | 2018 |
| Metric | CABO | REPL |
|---|---|---|
| Price | $51.57 | $8.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $125.67 | $5.67 |
| AVG Volume (30 Days) | 197.4K | ★ 6.0M |
| Earning Date | 04-30-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ 6.12 | N/A |
| Revenue | ★ $1,501,423,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.37 | $1.50 |
| 52 Week High | $180.74 | $13.24 |
| Indicator | CABO | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 76.20 |
| Support Level | $45.37 | $8.24 |
| Resistance Level | $117.15 | $9.01 |
| Average True Range (ATR) | 4.67 | 0.65 |
| MACD | 1.66 | 0.34 |
| Stochastic Oscillator | 34.60 | 95.38 |
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.